WO2004035594A1 - カルボキシペプチダーゼb阻害剤の製造用中間体 - Google Patents
カルボキシペプチダーゼb阻害剤の製造用中間体 Download PDFInfo
- Publication number
- WO2004035594A1 WO2004035594A1 PCT/JP2003/012501 JP0312501W WO2004035594A1 WO 2004035594 A1 WO2004035594 A1 WO 2004035594A1 JP 0312501 W JP0312501 W JP 0312501W WO 2004035594 A1 WO2004035594 A1 WO 2004035594A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- compound represented
- group
- hydrogen atom
- protecting group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 11
- 108090000087 Carboxypeptidase B Proteins 0.000 title abstract description 5
- 102000003670 Carboxypeptidase B Human genes 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 125000006239 protecting group Chemical group 0.000 claims abstract description 53
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 46
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000012453 solvate Substances 0.000 claims abstract description 14
- -1 Methoxy ((R) — 2-methyl-1- (3-phenylpropionylamino) propyl) phosphinylmethyl Chemical group 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 102000004882 Lipase Human genes 0.000 claims description 12
- 239000004367 Lipase Substances 0.000 claims description 12
- 108090001060 Lipase Proteins 0.000 claims description 12
- 238000010511 deprotection reaction Methods 0.000 claims description 12
- 235000019421 lipase Nutrition 0.000 claims description 12
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000005948 methanesulfonyloxy group Chemical group 0.000 claims description 5
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 5
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 claims 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 12
- 239000000543 intermediate Substances 0.000 abstract description 8
- 239000001257 hydrogen Substances 0.000 abstract description 7
- 230000003389 potentiating effect Effects 0.000 abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- 238000006243 chemical reaction Methods 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 19
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 229940040461 lipase Drugs 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 239000005416 organic matter Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 238000007259 addition reaction Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 2
- ZMIRFCWMDNOYEN-UHFFFAOYSA-N 1-phosphorosooxyethane Chemical compound CCOP=O ZMIRFCWMDNOYEN-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000006683 Mannich reaction Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- JWCJJGBLFQNCEL-QGZVFWFLSA-N [(2R)-2-(hydroxymethyl)-7-(phenylmethoxycarbonylamino)heptyl] acetate Chemical compound CC(=O)OC[C@@H](CO)CCCCCNC(=O)OCC1=CC=CC=C1 JWCJJGBLFQNCEL-QGZVFWFLSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 238000005976 benzyloxycarbonylation reaction Methods 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical group CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KNFPLMFTXFVFPA-UHFFFAOYSA-N lithium;bis(2-methylpropyl)azanide Chemical compound CC(C)CN([Li])CC(C)C KNFPLMFTXFVFPA-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000006502 nitrobenzyl group Chemical group 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 102000045222 parkin Human genes 0.000 description 2
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- YNOXCRMFGMSKIJ-NFNCENRGSA-N (2S,3S)-2-methylcitric acid Chemical compound OC(=O)[C@@H](C)[C@](O)(C(O)=O)CC(O)=O YNOXCRMFGMSKIJ-NFNCENRGSA-N 0.000 description 1
- KLRXDKRZWWJJQC-KHPPLWFESA-N (z)-2-methylideneoctadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCC(=C)C(O)=O KLRXDKRZWWJJQC-KHPPLWFESA-N 0.000 description 1
- 150000000185 1,3-diols Chemical group 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 1
- NKBWMBRPILTCRD-UHFFFAOYSA-N 2-Methylheptanoic acid Chemical compound CCCCCC(C)C(O)=O NKBWMBRPILTCRD-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical group O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- WGODGFXCRIJNLS-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylpyridine-3-carbonitrile Chemical compound CC1=NC(N)=C(C#N)C=C1C1=CC=NC=C1 WGODGFXCRIJNLS-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- XBEYHGZCUJSKOM-UHFFFAOYSA-N 4-tert-butyl-2-chlorobenzoic acid Chemical compound CC(C)(C)C1=CC=C(C(O)=O)C(Cl)=C1 XBEYHGZCUJSKOM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 238000006027 Birch reduction reaction Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- IPQGTUYSZQQSJP-UHFFFAOYSA-N C1(=CC=CC=C1)C.[K].C[Si](N[Si](C)(C)C)(C)C Chemical compound C1(=CC=CC=C1)C.[K].C[Si](N[Si](C)(C)C)(C)C IPQGTUYSZQQSJP-UHFFFAOYSA-N 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108020003338 D-alanine-D-alanine ligase Proteins 0.000 description 1
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102000043296 Lipoprotein lipases Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- XNCNNDVCAUWAIT-UHFFFAOYSA-N Methyl heptanoate Chemical compound CCCCCCC(=O)OC XNCNNDVCAUWAIT-UHFFFAOYSA-N 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- KBMNZBMTGZTXAY-SCSAIBSYSA-N N[C@@H](C(C)C)P(O)=O Chemical compound N[C@@H](C(C)C)P(O)=O KBMNZBMTGZTXAY-SCSAIBSYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 229910021604 Rhodium(III) chloride Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YIXQLKLBUFZDNS-UHFFFAOYSA-N [2-(acetyloxymethyl)-7-(phenylmethoxycarbonylamino)heptyl] acetate Chemical compound C(C)(=O)OCC(CCCCCNC(=O)OCC1=CC=CC=C1)COC(C)=O YIXQLKLBUFZDNS-UHFFFAOYSA-N 0.000 description 1
- 241000179532 [Candida] cylindracea Species 0.000 description 1
- XJUCCGJZENLZSA-UHFFFAOYSA-M [Rh]Cl Chemical class [Rh]Cl XJUCCGJZENLZSA-UHFFFAOYSA-M 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- DJHBQZYPXJJJMZ-UHFFFAOYSA-N benzyl 2-hydroxypiperidine-1-carboxylate Chemical compound OC1CCCCN1C(=O)OCC1=CC=CC=C1 DJHBQZYPXJJJMZ-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229910000072 bismuth hydride Inorganic materials 0.000 description 1
- BPBOBPIKWGUSQG-UHFFFAOYSA-N bismuthane Chemical compound [BiH3] BPBOBPIKWGUSQG-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- PXOIIZOTNBIMPZ-UHFFFAOYSA-N dichloromethane;oxalyl dichloride Chemical compound ClCCl.ClC(=O)C(Cl)=O PXOIIZOTNBIMPZ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- QKZWXPLBVCKXNQ-ROJLCIKYSA-N dipamp Chemical compound COC1=CC=CC=C1[P@@](C=1C=CC=CC=1)CC[P@@](C=1C(=CC=CC=1)OC)C1=CC=CC=C1 QKZWXPLBVCKXNQ-ROJLCIKYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HRTGCDRCJQKACR-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylprop-2-enoate Chemical compound COC(=O)C(=C)P(=O)(OC)OC HRTGCDRCJQKACR-UHFFFAOYSA-N 0.000 description 1
- BCDIWLCKOCHCIH-UHFFFAOYSA-M methylphosphinate Chemical compound CP([O-])=O BCDIWLCKOCHCIH-UHFFFAOYSA-M 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FXPDGSSSQUFIPW-UHFFFAOYSA-N oxaphospholane Chemical compound C1COPC1 FXPDGSSSQUFIPW-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- FCJSHPDYVMKCHI-UHFFFAOYSA-N phenyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1=CC=CC=C1 FCJSHPDYVMKCHI-UHFFFAOYSA-N 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- WJIBZZVTNMAURL-UHFFFAOYSA-N phosphane;rhodium Chemical compound P.[Rh] WJIBZZVTNMAURL-UHFFFAOYSA-N 0.000 description 1
- GTBPUYSGSDIIMM-UHFFFAOYSA-N phosphane;ruthenium Chemical compound P.[Ru] GTBPUYSGSDIIMM-UHFFFAOYSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- VUPQHSHTKBZVML-UHFFFAOYSA-J rhodium(3+);tetraacetate Chemical compound [Rh+3].[Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O VUPQHSHTKBZVML-UHFFFAOYSA-J 0.000 description 1
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- BFMKBYZEJOQYIM-UCGGBYDDSA-N tert-butyl (2s,4s)-4-diphenylphosphanyl-2-(diphenylphosphanylmethyl)pyrrolidine-1-carboxylate Chemical compound C([C@@H]1C[C@@H](CN1C(=O)OC(C)(C)C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)C1=CC=CC=C1 BFMKBYZEJOQYIM-UCGGBYDDSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- KOZCZZVUFDCZGG-UHFFFAOYSA-N vinyl benzoate Chemical compound C=COC(=O)C1=CC=CC=C1 KOZCZZVUFDCZGG-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657172—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and one oxygen atom being part of a (thio)phosphinic acid ester: (X = O, S)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3217—Esters of acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
- C07F9/4808—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
- C07F9/4816—Acyclic saturated acids or derivatices which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to an intermediate of a phosphinic acid derivative having a selective potent lipoxypeptidase B inhibitory activity, which is effective for treating and preventing various thrombosis, diseases caused by vascular disorders, and organ disorders caused by reduced fibrinolysis. It relates to the manufacturing method. Background art
- Phosphinic acid derivatives are similar to phosphate groups in that the geometry of the phosphinic acid moiety (one P (0) (0H) CH 2 —) mimics the transition state of enzymatic hydrolysis of peptide bonds. Therefore, it is used as the basic skeleton of protease inhibitors, inhibitors of enzymes that recognize phosphate groups.
- aminopeptidases eg, Proceeding of National Academy of Science of the United State of America,
- the present inventors produced a phosphinic acid derivative (16) having potent lipoxypeptidase B inhibitory activity described in International Publication W001 / 19836 by the method shown in the following process diagram 1.
- a phosphinic acid derivative (16) having potent lipoxypeptidase B inhibitory activity described in International Publication W001 / 19836 by the method shown in the following process diagram 1.
- benzyloxycarbonylation followed by bromination leads to (11), and in the presence of a base, (12) is reacted with getyl malonate.
- hydrolysis and Mannich reaction lead to (13) in two steps, '(13) and (14) undergo a conjugate addition reaction, and after deprotection, (16) is obtained. .
- the production method shown in process diagram 1 includes a conjugate addition reaction to obtain (13) to (15).
- the three-dimensional object cannot be controlled, and it is difficult to separate the generated diastereomer.
- the separation of diastereomers was relatively easy, but the (4S) -isopropyl-12-oxazolidinone (18) required for the synthesis of (19) was very expensive. Yes, and inferring from the reaction mechanism in the process of obtaining (19) to (21) It is expected that difficulties will be required to improve the selectivity.
- an object of the present invention is to provide a production method that can express an asymmetric point without using an expensive reagent, has high diastereoselectivity, and leads to a phosphine derivative in a shorter process. I have.
- the present inventors have conducted intensive studies and, as a result, have succeeded in finding a production method and an important intermediate for efficiently producing a phosphinic acid derivative which is a lipoxypeptidase B inhibitor. .
- 1 ⁇ and 1 2 may be the same or different each independently represent a protecting group which can be removed in a hydrogen atom or an easily,
- R 3 represents a hydrogen atom or an easily removable protecting group
- R 4 represents a hydrogen atom or an easily removable protecting group
- n an integer of 1 to 8.
- R 1 and R 2 each independently may be the same or different and represent a hydrogen atom or a protecting group which can be easily removed;
- R 4 represents a hydrogen atom or an easily removable protecting group
- R 5 is a hydroxyl group
- 1 OR 6 R 6 represents a protecting group which can be easily removed
- 4 is benzyl group 2—Oxoxoxazolidine represents a 1-yl group
- n an integer of 0 to 7.
- R 1 and R 2 may be each independently the same or different, and represent a hydrogen atom or an easily removable protecting group
- R 3 represents a hydrogen atom or an easily removable protecting group
- n an integer of 1 to 8
- the two R 3 are the same and may be different. ];
- 1 ⁇ Pi 1 2 may be the same or different each independently represent a hydrogen atom or a readily removable protecting group
- n an integer of 1 to 8.
- m represents an integer of 1 to 8.
- the compound represented by the general formula (3a) is acylated by lipase treatment or treatment using a chiral compound as a catalyst to selectively synthesize the compound represented by the general formula (3b). Protection and / or deprotection steps;
- 1 ⁇ Pi 1 2 may be the same or different each independently represent a hydrogen atom or a readily removable protecting group
- R 3 represents a hydrogen atom or an easily removable protecting group
- n m :! Represents an integer from 8 to 8,
- R 7 represents a halogen atom, a methanesulfonyloxy group, a ⁇ -tonolenesulfonyloxy group, or a trifluoromethanesulfonyloxy group.
- R 4 represents a hydrogen atom or a protecting group which can be easily removed.
- a method comprising:
- m represents an integer of 1 to 8.
- the compound represented by the general formula (3a) is acylated by lipase treatment or treatment using a chiral compound as a catalyst to selectively synthesize the compound represented by the general formula (3b). Protection and deprotection steps;
- R 3 represents a hydrogen atom or an easily removable protecting group
- n an integer of 1 to 8
- R 7 represents a halogen atom, a methanesolephoninoleoxy group, a ⁇ -tonorenesnolehoninoleoxy group, or a trifluoromethanesulfonyloxy group.
- R 4 represents a hydrogen atom or a protecting group which can be easily removed.
- a production method comprising a step of oxidizing and, if necessary, deprotecting the protected functional group
- m represents an integer of 1 to 8.
- R 4 represents a hydrogen atom or an easily removable protecting group
- R 5 is a hydroxyl group
- 1 OR 6 R 6 represents a protecting group which can be easily removed
- 4 1-isopropyl poryl 2-oxooxozolidine-13-yl group 4 benzyloxy 2- Oxoxoxazolidine represents a 3-yl group.
- R 1 and R 2 may be independently the same or different and each represent a hydrogen atom or an easily removable protecting group
- n an integer from 0 to 7
- m represents an integer of 1 to 8.
- R 4 represents a hydrogen atom or an easily removable protecting group
- R 5 is a hydroxyl group, 1 OR 6 (R 6 represents a protecting group which can be easily removed), 4-isopropyl porphyr-2-oxooxozolidine-13-yl group, or 4-benzyl-2 —Oxoxoxazolidine — represents a 3-yl group. ], as well as
- R 1 represents a hydrogen atom or an easily removable protecting group
- n an integer of 1 to 7.
- the present invention relates to an intermediate for producing a compound represented by the general formula (5), which is a phosphinic acid derivative which is a potent carboxypeptidase B inhibitor, and a method for producing the same. Things.
- R 1 and R 2 may be independently the same or different, and represent a hydrogen atom or a protecting group that can be easily removed.
- the protecting group that can be easily removed include, for example, methoxycanolevonyl group, t-butyloxycanoleponyl group, benzyloxycanoleponyl group, methoxybenzyloxycarbonyl group, and nitrobenzyloxycarbonyl group.
- R 1 and R 2 may represent a phthalimid group bonded to each other at the terminal to form a ring.
- a t-butyloxycarbonyl group or a benzyloxycarbonyl group is used, and more preferably, a benzyloxycarbonyl group is used.
- R 3 represents a hydrogen atom or a protecting group that can be easily removed.
- Protecting groups that can be easily removed include, for example, methyl, methoxymethyl, methoxyethoxymethyl, benzyloxymethyl, t-butyloxymethyl, methylthiomethyl, trimethylsilylethyl, Tetrahydrobilanyl, ethoxyxyl, t-butyl, aryl, methoxyphenyl, benzyl, methoxybenzyl, dimethoxybenzyl, nitrobenzyl, diphenylmethyl, trityl, trimethylsilyl, triethylsilyl Group, t-butyldimethylsilyl group, diphenylmethylsilyl group, formyl group, acetyl group, propionyl group, butyryl group, chloroacetylinole group, trifluoroacetyl group, benzoyl group, t-butylbutylino
- an acetyl group, a t-butyl benzoyl group, a propionyl group, a benzoyl group and the like are mentioned, and more preferably, an acetyl group and a t-butyl benzoyl group.
- R 4 represents a hydrogen atom or an easily removable protecting group.
- Protecting groups that can be easily removed include, for example, methyl, ethyl, methoxymethyl, methoxetoxymethyl, benzyloxymethyl, t_butyloxymethyl, methylthio Methyl group, trimethylsilylethyl group, ethoxyxyl group, t-butyl group, aryl group, methoxyphenyl group, benzyl group, paramethoxybenzyl group, nitrobenzyl group, benzhydryl group, trityl group, trimethylsilyl group, trimethylsilyl group, Or a t-butyldimethylsilyl group.
- a methyl group, an ethyl group, a t-butyl group, a benzyl group and the like are mentioned, and more preferably, a methyl group and an ethyl group are shown.
- n represents an integer of 1 to 8. Preferably, it is 4-8. More preferably, the value is 5.
- R 5 is a hydroxyl group, —OR 6 (R 6 represents a protecting group which can be easily removed), 4-isopropyl-pyr-2-oxooxozolidine-13-yl group, or 4-benzyl-2-yl Oxoxoxazolidine-1-yl group.
- R 6 represents a protecting group which can be easily removed
- 4-isopropyl-pyr-2-oxooxozolidine-13-yl group or 4-benzyl-2-yl Oxoxoxazolidine-1-yl group.
- a hydroxyl group or —OR 6 is used.
- Examples of the easily removable protecting group represented by R 6 include, for example, a methyl group, an ethyl group, a methoxymethyl group, a methylthiomethyl group, a tetrahydrobilanyl group, a trimethylsilylethoxymethyl group, a benzyloxymethyl group, a trichloroethyl group, Trimethylsilylethyl, t-butyl, aryl, benzyl, triphenylmethyl, diphenylmethyl, p-methoxybenzyl, (+)-menthyl, (-)-menthyl, trimethylsilyl, triethylsilyl And a t-butyldimethylsilyl group.
- Preferable examples include a methyl group and an ethyl group, and more preferable examples include a methyl group.
- n represents an integer of 0 to 7, preferably 3 to 7, and more preferably 4.
- R 7 represents a halogen atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, or a trifluoromethanesulfonyloxy group.
- Preferred are a halogen atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, and the like, and more preferred are an iodine atom and a bromine atom.
- the 1,3 diol form (3a) can be produced by reducing the ester from the malonate getyl ester form (12) shown in the process diagram 1.
- the reduction reaction can be performed, for example, by using lithium aluminum hydride, bismuth hydride (2-methoxy (Sietoxy) Metal hydride represented by sodium anolemminium, lithium borohydride, sodium borohydride, aluminum diisobutynole, aluminum hydride, and triethoxysilane, and Birch reduction and Bouvault-Blanc reduction Dissolved metal, borane tetrahydrofuran complex, porane dimethyl sulfide complex, and borane compound represented by 9-porabicyclo [3.3.1] nonane can be used. .
- lithium aluminum hydride bismuth hydride (2-methoxy (Sietoxy) Metal hydride represented by sodium anolemminium, lithium borohydride, sodium borohydride, aluminum diisobutynole, aluminum hydride, and triethoxysilane
- Birch reduction and Bouvault-Blanc reduction Dissolved metal borane tetrahydr
- a solvent inert to the reaction may be used alone or as a mixture, and an additive may be added as necessary.
- the reaction time ranges from 0.5 hours to 72 hours, preferably from 2 hours to 24 hours, and the reaction temperature ranges from 178 ° C to 150 ° C, preferably from 178 ° C to 100 ° C. C.
- examples of the acyl donor include carboxylic acid biellester or carboxylic acid phenyl ester, preferably vinyl acetate, vinyl propionate, vinyl butyrate, vinyl benzoate, phenyl acetate, phenyl propionate, phenyl butyrate, or Phenyl benzoate, more preferably vinyl acetate, can be used.
- an inert solvent tetrahydrofuran, ethyl acetate, methylene chloride, methylenoleate, acetone, chlorophonolem, benzene, isopropynoleether, acetonitrile, dioxane, toluene, dimethylformamide, dimethylene) Sulfonic acid, etc.
- an inert solvent tetrahydrofuran, ethyl acetate, methylene chloride, methylenoleate, acetone, chlorophonolem, benzene, isopropynoleether, acetonitrile, dioxane, toluene, dimethylformamide, dimethylene
- acyl donor itself is used as a solvent, and if necessary, molecula sieve 4A or the like can be added.
- enzymes such as Pseudomonas fluorecens lipase, Candida cylindracea lipase, Pseudomonas sp. Lipase ⁇ lipoprotein lipase, and porcine pancreatic lipase can be used as the linose.
- the reaction temperature is between 20 ° C and 60 ° C
- the reaction time is preferably 0 ° C to 40 ° C, and the reaction time is 0.5 hour to 72 hours, preferably 2 hours to 24 hours.
- the compound represented by the general formula (3b) can be obtained by asymmetric acylation of the compound represented by the general formula (3a).
- the compound represented by the general formula (3) obtained by subjecting the compound represented by the general formula (3) to diasylation by a conventional method to obtain a compound represented by the general formula (3a) 3b) can be obtained.
- an alcohol methanol, ethanol, n-propanol, i-prono ⁇ ⁇ 0- norole, n-butanol, t-butanol, etc.
- a buffer phosphate buffer, acetate buffer, etc.
- the compound represented by the general formula (3b) can also be obtained by the method described in Chemistry Letters, 26, (2002).
- a compound represented by the general formula (3a) is used as a raw material, and (S) _1-methyl-2-(((dihydroisoindole-l-2-yl) methyl) pyrrolidine, (S) —
- an optically active diamine compound such as 1-methyl-1- (benzylmethylaminomethyl) pyrrolidine
- a solvent inert to the reaction tetrahydrofuran, ethyl acetate, methylene chloride, dimethyl ether, acetone, Chlorophonolem, benzene, isopropyl ether, acetonitrile, n- propionitrile, dioxane, toluene, dimethylformamide or dimethylsulfoxide), preferably in methylene chloride or n-propionitrile.
- the reaction is carried out using a carboxylate, preferably chlorobenzoic acid, or chloro-4-t-butylbenzoic acid.
- the reaction temperature is from 180 to 150 ° C, preferably from 178 to 20 ° C, and the reaction time is from 0.5 to 72 hours, preferably from 2 to 24 hours. Time.
- the compound represented by the general formula (3b) can be obtained by asymmetric acylation.
- the compound represented by the general formula (6) is a primary water compound represented by the general formula (3b).
- the acid group can be obtained by halogenation, sulfonic esterification, and preferably iodination in a usual manner.
- the general formula (7) is based on the method described in W001 / 19836 using (R) -1-amino-2-methylpropylphosphinic acid described in J. Chem. Soc. Parkin Trans. 1, 2845 (1984) as a raw material. used, it can be obtained by modifying with R 4, if necessary.
- the compound represented by the general formula (7) is activated by a silyl group or the like as necessary, and further, if necessary, hexamethyldisilazane lithium salt, hexamethyldisilazane sodium salt, hexamethyl
- the reaction can be carried out by adding a compound represented by the general formula (6) in the presence of a base such as disilazane potassium salt, lithium diisobutylamide, sodium hydride or potassium hydride.
- the reaction is carried out in an inert solvent (tetrahydrofuran, ethyl acetate, methylene chloride, getyl ether, chloroform, benzene, isopropynoleate //, dioxane, tonolen, dimethinolehonolemamide, dimethyl sulfoxide, etc. ) May be used alone or as a mixture, and the reaction temperature is from 178 ° C to 150 ° C, preferably from ⁇ 78 ° C to 20 ° C, and the reaction time is 0.5 hour. 772 hours, preferably 2 ⁇ 24 hours.
- an inert solvent tetrahydrofuran, ethyl acetate, methylene chloride, getyl ether, chloroform, benzene, isopropynoleate //, dioxane, tonolen, dimethinolehonolemamide, dimethyl sulfoxide, etc.
- the compound represented by the general formula (9) can be obtained by protecting the amino group of the amino alcohol with, and oxidizing it by a usual method.
- the compound represented by the general formula (9) can equilibrate with a compound represented by the general formula (9 ′) in a general solvent when R 2 is a hydrogen atom.
- the compound represented by the general formula (2) can be synthesized according to the method described in Tetrahedron Letters, 5201, (1988). Specifically, the compound represented by the general formula (7) is activated by a silyl group or the like as necessary, and then, if necessary, hexamethyldisilazane lithium salt, hexamethyldisilazane sodium salt, or hexamethyldisilazane. By adding a base such as silazane potassium salt, lithium diisobutylamide, sodium hydride, potassium hydride, sodium methoxide, or sodium ethoxide, and adding the compound represented by the general formula (8) The reaction can be performed.
- a base such as silazane potassium salt, lithium diisobutylamide, sodium hydride, potassium hydride, sodium methoxide, or sodium ethoxide
- the solvent examples include solvents inert to the reaction (tetrahydrofuran, ethyl acetate, methylene chloride, getyl ether, chlorophonolem, benzene, methanolone, ethanol, isobutynoleanolone, n-butynoleanolone, t-butyl alcohol, isopropyl ether, dioxane, toluene, dimethyl honolemamide, dimethyl sulfoxide, etc.
- the reaction temperature is from 180 to 150 ° C. ° C, preferably from 1 78 ° C to 50 ° C.
- the reaction time is 0.5 hour to 72 hours, preferably 2 hours to 24 hours.
- the compound represented by the general formula (2) can be obtained by adding the compound represented by the general formula (9) or (9 ′) without performing post-treatment and performing the reaction. it can.
- the reaction temperature is 1 78 ° C to 150 ° C, preferably _ 78 ° C to 50 ° C, and the reaction time is 0.5 hour to 72 hours, preferably 2 hours to 24 hours. Time.
- a phosphinic acid derivative which is a CPB inhibitor represented by the formula (5) can be obtained.
- the compound represented by the general formula (2) or, if necessary, the general formula (2) The reaction can be carried out by treating a compound obtained by deprotecting the compound represented by the following with the following catalyst system.
- the catalyst system include rhodium catalysts such as 1,5-cycloocta- gen rhodium (I) chloride dimer, rhodium (II) acetate dimer, rhodium (III) chloride, and (+)-1-(t 1-butoxycarbonyl) 1 4-diphenyl ⁇ phosphino 2-((dibuenylenephosphino) methyl) pyrrolidine (BPPM), (+)-2,3-O-isopropylidene 1,2,3-dihydroxy 1 1,4-bis (dipheninolephosphino) butane (DI OP), (+)-4,5 bis (bis (4'-methoxy-1 3 ', 5,5-dimethylphenyl) phosphinomethyl) 1 2 , 2-Di
- the hydrogen source it is possible to use hydrogen gas, alcohols such as ethanol and 2-propanol, or salts of formic acid and amines such as triethylamine and phenethylamine.
- an inert solvent tetrahydrofuran, isoptyl alcohol, n-butanol, ethynole acetate, methylene chloride, ethynoleether, acetone, methanol, clonor honolem, ethanol, t-butanol, Benzene, isopropyl ether, dioxane, toluene, dimethylformamide, dimethylsulfoxide, etc.) alone or in combination.
- the reaction temperature is from 1 78 ° C to 150 ° C, preferably from 0 ° C to 100 ° C, and the reaction time is from 0.5 hour to 72 hours, preferably from 2 hours to 24 hours.
- the reaction using hydrogen gas can be carried out under an internal pressure of 1 atm to 10 atm, preferably 1 atm to 5 atm.
- the obtained general formula (2 The compound represented by 3) can be led to the final substance (5) through a deprotection step if necessary.
- the compounds represented by the general formulas (1) to (4) in the present invention may have one or more asymmetric carbon atoms depending on the type of the substituent, and may have one or two asymmetric carbon atoms.
- Stereoisomers such as optically active isomers based on the above asymmetric carbons and diastereoisomers based on two or more asymmetric carbons may exist.
- the compound represented by the general formula (2) may have an E or Z geometric isomer based on carbon or a carbon double bond. All of these substances are included in the scope of the present invention.
- the compounds represented by the general formulas (1) to (4) in the present invention may exist as salts.
- the salt include lithium metal, sodium salt, potassium metal salt, magnesium earth salt, alkaline earth metal salt such as calcium salt, aluminum salt, and zinc salt.
- Inorganic acid salts such as acetic acid, hydrochloride, sulfate, nitrate and the like; organic acid salts such as acetate, trifluoroacetate and methanesulfonic acid;
- the compounds represented by the general formulas (1) to (4) or salts thereof in the present invention may exist as hydrates or solvates.
- the type of the solvent that forms the solvate is not particularly limited. Examples thereof include alcohols such as methanol, ethanol, and isopropanol, and ethers such as tetrahydrofuran.
- the salts, hydrates, or solvates of the compounds represented by the general formulas (1) to (4) in the present invention are included in the scope of the present invention.
- Example 1 Production method A
- an intermediate for production for efficiently producing a phosphuvic acid derivative which is a potent lipoxypeptidase B inhibitor.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003266713A AU2003266713A1 (en) | 2002-10-01 | 2003-09-30 | Intermediate for producing carboxypeptidase b inhibitor |
JP2004544914A JPWO2004035594A1 (ja) | 2002-10-01 | 2003-09-30 | カルボキシペプチダーゼb阻害剤の製造用中間体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-288969 | 2002-10-01 | ||
JP2002288969 | 2002-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004035594A1 true WO2004035594A1 (ja) | 2004-04-29 |
Family
ID=32104952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/012501 WO2004035594A1 (ja) | 2002-10-01 | 2003-09-30 | カルボキシペプチダーゼb阻害剤の製造用中間体 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2004035594A1 (ja) |
AU (1) | AU2003266713A1 (ja) |
WO (1) | WO2004035594A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008029754A1 (fr) * | 2006-09-04 | 2008-03-13 | Meiji Seika Kaisha, Ltd. | Procédé de fabrication d'un acide aminophosphinylbutanoïque optiquement actif |
US7772426B2 (en) | 2005-03-29 | 2010-08-10 | Meiji Seika Kaisha, Ltd. | Method for producing L-2-amino-4-(hydroxymethylphosphinyl)-butanoic acid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1152004A1 (en) * | 1999-09-14 | 2001-11-07 | Meiji Seika Kaisha Ltd. | Phosphonic acid derivatives having carboxypeptidase b inhibitory activity |
-
2003
- 2003-09-30 JP JP2004544914A patent/JPWO2004035594A1/ja active Pending
- 2003-09-30 AU AU2003266713A patent/AU2003266713A1/en not_active Abandoned
- 2003-09-30 WO PCT/JP2003/012501 patent/WO2004035594A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1152004A1 (en) * | 1999-09-14 | 2001-11-07 | Meiji Seika Kaisha Ltd. | Phosphonic acid derivatives having carboxypeptidase b inhibitory activity |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772426B2 (en) | 2005-03-29 | 2010-08-10 | Meiji Seika Kaisha, Ltd. | Method for producing L-2-amino-4-(hydroxymethylphosphinyl)-butanoic acid |
WO2008029754A1 (fr) * | 2006-09-04 | 2008-03-13 | Meiji Seika Kaisha, Ltd. | Procédé de fabrication d'un acide aminophosphinylbutanoïque optiquement actif |
US8076503B2 (en) | 2006-09-04 | 2011-12-13 | Meiji Seika Pharma Co., Ltd. | Process for production of optically active aminophosphinylbutanoic acids |
RU2442787C2 (ru) * | 2006-09-04 | 2012-02-20 | Мейдзи Сейка Фарма Ко., Лтд. | Способ получения оптически активных аминофосфинилбутановых кислот |
Also Published As
Publication number | Publication date |
---|---|
AU2003266713A1 (en) | 2004-05-04 |
JPWO2004035594A1 (ja) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014028969B1 (pt) | Processo de produção melhorado de treprostinil e seus derivados | |
US5767316A (en) | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | |
Öhrlein et al. | Chemo‐enzymatic approach to statin side‐chain building blocks | |
JP5973459B2 (ja) | ネビボロールの調製のための方法 | |
JPH0623150B2 (ja) | 光学活性3−ヒドロキシブタン酸類の製造方法 | |
JP2008509102A (ja) | ヒドロラーゼを用いるcis−配置3−ヒドロキシシクロヘキサンカルボン酸誘導体のエナンチオマー体を製造する方法 | |
JP4142444B2 (ja) | 2−アゼチジノン誘導体の製造方法 | |
JP2004331644A (ja) | モナチン類の製造法 | |
WO2004035594A1 (ja) | カルボキシペプチダーゼb阻害剤の製造用中間体 | |
JPH06172276A (ja) | β−ラクタム前駆体からタキソール型化合物を製造する方法 | |
CN112585116B (zh) | (2s,3r,4r)-4,5-二羟基异亮氨酸及衍生物的合成 | |
JPH10245369A (ja) | セリン誘導体の製造方法 | |
JP4991543B2 (ja) | ジアリールシクロアルキル誘導体の製造方法 | |
US8785690B2 (en) | Thioamide compound, method for producing thioamide compound, method for producing [(4R,6R)-6-aminoethyl-1,3-dioxan-4-yl]acetate derivative, and method for producing atorvastatin | |
KR101399551B1 (ko) | 광학적으로 활성인 사이클로펜텐온의 제조방법 및 그로부터제조된 사이클로펜텐온 | |
JP2010195737A (ja) | 光学活性コンボルタミジン誘導体の製造方法 | |
CA2456255A1 (en) | Protected 3.5-dihydroxy-2.2-dimethyl-valeroamides for the synthesis of epothilone and derivatives and method for the production and use thereof | |
WO2017168438A1 (en) | Process for preparing pure allyl protected keto derivative | |
JP2010031004A (ja) | 新規イミダゾール誘導体及びその製造方法並びに該イミダゾール誘導体を利用したヒスチジンアミド誘導体の製造方法 | |
JP4945823B2 (ja) | 光学活性ビニルケトン誘導体およびこれを用いた光学活性アミノジオール類の製造方法 | |
KR101954281B1 (ko) | 광학적으로 활성인 3-하이드록시피페리딘 또는 이의 유도체의 입체선택적 제조방법 | |
JP2007204384A (ja) | 光学活性リン酸誘導体およびこれを用いた光学活性スフィンゴシン1−リン酸誘導体の製造方法 | |
JP3410452B2 (ja) | 光学活性イノシトールトリフォスフェートの製造法 | |
JP3855323B2 (ja) | 3−アミノ−2−オキソ−1−ハロゲノプロパン誘導体の製造方法 | |
JP3173850B2 (ja) | 光学活性イノシトール誘導体の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004544914 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |